Invention of QR 678 ®hair growth therapy:
The QR 678 ®is a proprietary, first in class hair fall & hair regrowth therapy, which has revolutionized the treatment of hair fall in alopecia. This formulation has been named QR678 inspired by the new generation ubiquitous presence of “Quick Response“ QR code. 678 in Morse Code signifies “there is no answer”. This formulation has been named QR678™ to signify a “Quick Response to a disease which earlier had no answer”.
The QR 678 ® was invented by a team lead by Dr. Debraj Shome, a renowned Facial Plastic Surgeon and Dr. Rinky Kapoor, a well-known dermatologist. Dr. Shome & Dr. Kapoor co-founded The Esthetic Clinics®, which are a chain of top class dermatology & plastic surgery centers located in various cities in India.
How does it work?
The QR 678 ® therapy arrests hair fall & increases the thickness, number & density of existing hair follicles, leading to greater coverage in patients with alopecia. Since, the polypeptides used in QR 678 ® are anyways present in scalp full of hair (they get decreased in scalps which have hair fall), it is the enrichment of the scalp skin with these polypeptides which cause hair growth. Since these polypeptides are anyways normally present in the scalp, replenishing the scalp with these is not artificial and does not have any side effects.
The QR 678 ®therapy works very well in androgenetic alopecia or male pattern baldness & female pattern hair loss. The QR 678 ® therapy has also demonstrated encouraging results in post chemotherapy induced hair loss, treatment of hair conditions like seborrheic dermatitis & in immunogenic diseases like alopecia areata.
The team has formulated a blend of bio-mimicking polypeptides (analogous to naturally occurring human protein factors) with amino acids and minerals to produce astonishing results, compared to Platelet Rich Plasma (PRP) based therapy or Stem cells therapy or even in cases otherwise refractory to Minoxidil or Finasteride or a combination therapy. This treatment works very well in male and female pattern baldness, and even in post hair transplant cases. In early cases of hair loss (Norwood Grade I – III), this treatment is actually showing better results than hair transplant surgery.
How was it invented & Invention Timelines:
In 2006, While working on a drug for ocular & neural cancers, Dr. Shome stumbled upon potential causes of hair fall, in the animal trial he was pursuing.
This research on Retinoblastoma conducted in collaboration with the Indian Institute of Technology, Mumbai, India (IIT) threw up an interesting phenomenon of hair loss in the animal model.
From 2006-2008, Determined pursuit of this insight leads to identification of growth factors and polypeptides possibly influencing hair growth. Signal transduction of proteins, based on animal models, were used to identify 5 naturally occurring growth factors/ polypeptides in humans.
In 2009, the First in Human trial commenced to study dose ranging and evolve optimum concentration mix to yield the best in class results.
The QR 678 ® hair formulation therapy was featured on Times Of India (India’s largest read English news daily), on first page, all editions on September 19th, 2010.
Subsequently, from 2013-2016, a Phase III clinical user trial in a large cohort of 1000 patients of both genders was completed, to test efficacy & safety of the proposed formulation. This clinical trial was published in a very reputed, top, American Journal, Journal of Cosmetic & Laser Therapy, in 2017. After 8 sessions, global photographs showed improvement from baseline for 71% patients, a decreased score for 10% patients, & no change in score for 19% patients. The findings of this study suggest that the beneficial clinical effects of this QR 678 ® hair formulation therapy are similar in men & women, across different age groups, & in patients irrespective of the presence of metabolic disorders like diabetes, hypertension, hypercholesterolemia etc.
Clinical Trial Data
QR678™ in India has been through a Phase III open label, prospective, single arm interventional CLINICAL Trial, in which 1000 patients were given mesotherapy administration into the scalp skin. The treatment regimen comprised 8 mesotherapy sessions, 3 to 4 weeks apart, till 8 sessions were completed. Hair pull test was performed, before every session. Videomicroscopic & global images were taken at baseline, fourth session, eighth session, & 2 months after the completion of the 8 sessions. Relevant safety assessments through physical examination, questionnaires & appropriate laboratory examination were conducted throughout the study.
The treatment was effective in improving the appearance of scalp hair & slowing the loss of hair in men & women with patterned hair loss. Improvement in hair growth with therapy was evident as early as after 4 sessions for all measured endpoints. At one year, a statistically significant increase in total hair count (P=0.002) continued to be seen. After 8 sessions, global photographs showed improvement from baseline for 71% patients, a decreased score for 10% patients, & no change in score for 19% patients.
The findings of this study suggest that the beneficial clinical effects of this therapy are similar in men & women, across different age groups, & in patients irrespective of the presence of metabolic disorders like diabetes, hypertension, hypercholesterolemia etc. Moreover, results indicate that therapy was also effective in controlling hair loss in 14 post hair transplant patients. There was a negative correlation between the duration & stage of hair loss, & the degree of improvement.
Haematology & serum biochemical analysis were performed at baseline, sessions 4, 8 & then 2 months post the 8th session. There was no significant change in the biochemical values from the administration of QR678.
Intellectual Property Assets:
A composition & mechanism of administration patent was awarded to the QR 678 ® hair formulation on 11th July 2017, by the United Stated Patent & Trademark Office (USPTO) – USA patent no 9, 700, 504 B2. Details of the patent are available below:
The Indian Patent Application was granted a composition and method of administration comprehensive patent, vide Indian Patent No. IN310925, granted on 5th April, 2019.
The Indian FDA gave an approval for commercial manufacturing & sale in March 2019.